A Study to Evaluate Efficacy and Safety of HS-10374 for Mild-to-moderate Plaque Psoriasis
ConditionPsoriasis
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorHansoh BioMedical R&D Company
About this trial
This study has been designed to explore the clinical efficacy and safety of HS-10374 in the treatment of mild-to-moderate plaque psoriasis.
Eligibility criteria
Qualifiers
Male or female subjects between the ages of 18-70 years
Diagnosis of plaque psoriasis for at least 6 months
sPGA score of 2-3, BSA 2-15%, PASI score 2-15
Subject must be inadequately controlled with, or intolerant of at least one topical therapy
Disqualifiers
Diagnosis of non-plaque psoriasis or drug-induced psoriasis
Recent history of infection, history or risk of serious infection
Any major illness or evidence of unstable condition of major organ systems including psychiatric disease
Any condition possibly affecting the PK process of the study drug
Trial design
Treatments tested in this trial
- HS-10374 6mg tablets
- HS-10374-matched placebo tablets
Treatment groups
305 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov